drugset / Trial / NCT04615949
Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Non-critical patients, hospitalized within the previous 24 hours who tested positive for COVID-19 and have a prior history of cardiovascular disease (CVD) and/or significant risk factors for CVD will be treated for 28 days.
Timeline
- Start
- 2021-04-30
- Primary completion
- 2022-11-30
- Completion
- 2022-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 7.5 mg/kg | Oral |